Pharsight

Orbactiv patents expiration

ORBACTIV's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5998581 MELINTA THERAP Reductive alkylation of glycopeptide antibiotics
Nov, 2017

(6 years ago)

US5840684 MELINTA THERAP Glycopeptide antibiotic derivatives
Nov, 2020

(3 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592 MELINTA THERAP Methods of treatment using single doses of oritavancin
Aug, 2029

(5 years from now)

US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin
Apr, 2030

(5 years from now)

US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(11 years from now)

Orbactiv is owned by Melinta Therap.

Orbactiv contains Oritavancin Diphosphate.

Orbactiv has a total of 5 drug patents out of which 2 drug patents have expired.

Expired drug patents of Orbactiv are:

  • US5998581
  • US5840684

Orbactiv was authorised for market use on 06 August, 2014.

Orbactiv is available in powder;intravenous dosage forms.

Orbactiv can be used as treatment of bacterial skin and skin structure infections using a single dose, treatment of bacterial skin and skin structure infections.

Drug patent challenges can be filed against Orbactiv from 07 August, 2023.

The generics of Orbactiv are possible to be released after 16 July, 2035.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 06, 2019
Generating Antibiotic Incentives Now(GAIN) Aug 06, 2024

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 07 August, 2023

Market Authorisation Date: 06 August, 2014

Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ORBACTIV family patents

Family Patents